Fighting XDR Typhoid: A Hospital Based Study on Clinical Aspects and Treatment Outcome in Tertiary Care Hospital

Objective: The main aim of this study is to find Clinical Aspects and Treatment Outcome in drug resistant Typhoid. Methodology: Total 120 patients participated in this study. Individuals who received a diagnosis of XDR S.Typhi through a blood culture test were identified from the registry of both healthcare facilities. The medical data of patients suffering from typhoid fever who received treatment as either a hospital inpatient or outpatient between April 1, 2022, and June 30, 2022, were examined for the purpose of screening for inclusion in this investigation. Only typhoid patients who tested positive for S.Typhi in a  test to culture blood and the manifestation of insusceptibility to the five classifications of antimicrobials (ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, fluoroquinolone, and 3rd generation cephalosporin (ceftriaxone or cefixime) were examined for potential incorporation in this inquiry. Results: Among the 120 cases of XDR Typhoid, n= 35 (29.16%) were managed exclusively with azithromycin, while 40 (33.33%) were solely administered meropenem. The remaining 45(37.5%) received a combination of both azithromycin and meropenem. Two patients could not recover after receiving Azithromycin. Full recovery seen in Meropenem. Four patients couldn’t recover from combination therapy. Conclusion:  Escalating antibiotic resistance in Salmonella enterica has rendered it a complex ailment to address. Measures ought to be implemented to enhance antibiotic prescription protocols and establish consistent recommendations for the management of highly resistant strains of Salmonella enterica.